Sequenom to launch new prenatal test next month

|By:, SA News Editor

Sequenom (SQNM +3.6%) subsidiary Sequenom Laboratories plans to launch its VisibiliT laboratory-developed test (LDT) next month in ex. U.S. markets. The test utilizes chromosomal material from chromosomes 18 and 21 in combination with maternal age and fetal fraction to generate a personalized risk score for fetal trisomies such as Down syndrome and Edwards syndrome. The test is performed using a maternal blood sample and applies to a single gestation pregnancy considered to be at average risk.

The company intends to offer the test in the U.S. after insurance coverage is established.